Nasdaq GlobeNewswire

XBiotech Provides Update on Xilonix™ Phase III Programs in US and EU

Del

AUSTIN, Texas, 2016-07-23 00:45 CEST (GLOBE NEWSWIRE) --

XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ antibody therapies, said today that the Independent Data Monitoring Committee (DMC) for the XCITE Phase III clinical study of Xilonix™ for the treatment of colorectal cancer, recently recommended study continuation without any amendment to the study design. The DMC convened as scheduled, subsequent to the enrollment of 400 patients into the study.

The DMC mandate is to “monitor for early evidence of treatment harm and to routinely recommend to continue, suspend, or otherwise modify enrollment based on their findings.” The DMC did not have any recommendations for the Company regarding any need for changes to the study operation. This is viewed as a positive assessment with respect to safety, as well as to key aspects of study execution. Another DMC meeting is scheduled to occur either after 600 patients have been enrolled, or potentially earlier if the study meets its first planned efficacy analysis milestone. Xilonix has been granted FDA fast-track review and the XCITE study is on schedule to reach its enrollment milestones in 2016.

The Company’s marketing authorization application for Xilonix for the treatment of colorectal cancer remains on schedule to achieve a decision in 2016 by the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). The Company recently scheduled an in-person meeting with the CHMP. The Company believes the meeting will help advance the marketing authorization process and has agreed with the CHMP for the MAA to be reviewed under the standard assessment timetable, rather than the accelerated review timeline that was granted in April 2016. The Company says that the standard timetable will provide additional time to conduct the MAA process. The standard timetable is expected to add approximately 60-days to the review proceedings.

About Xilonix™ and Interleukin-1 alpha (IL-1α) 
Xilonix is the first monoclonal antibody to specifically target and neutralize interleukin-1 alpha (IL-1α), one of the most potent inflammatory signaling molecules. The IL-1 pathway in general, and IL-1α in particular, is a desirable target for anti-cancer therapy because of its potential role in both local and systemic effects of cancer.i,ii IL-1α in the tumor microenvironment is known to promote angiogenesis (the growth and spread of tumors), as well as mediate symptoms such as metabolic dysregulation (e.g., loss of weight and muscle mass), fatigue and anxiety associated with advanced cancer.

About True Human™ Therapeutic Antibodies
Unlike previous generations of antibody therapies, XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Apte RN, Voronov E. Interleukin-1 a major pleiotropic cyto-kine in tumor-host interactions. Can Biol. 2002;12:277–290.

ii Dinarello CA.  Interleukin-1α neutralisation in patients with cancer.  Lancet Oncol. 2014;15(6):552-553.

         Investor Relations
         Scott Whitehurst
         Phone: 512.386.2993
         Email: swhitehurst@xbiotech.com
         
         Media Ex-U.S.
         Jonathan Kearney
         +44 20 8618 2755
         
         Media U.S.
         Ashley Cadle
         310.463.0143

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Atico Reports 2017 Fourth Quarter and Full Year Production Results22.1.2018 22:30Pressemelding

VANCOUVER, British Columbia, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSXV:ATY) (OTC:ATCMF) is pleased to announce operating results for the three and twelve month periods ended December 31, 2017 from its El Roble mine. Production totaled 5.33 million pounds of copper with 2,972 ounces of gold for the fourth quarter ("Q4 2017") and 20.63 million pounds of copper with 10,923 ounces of gold in concentrates for the full year 2017. "Atico has successfully concluded its fourth full year of operating the El Roble mine, exceeding 2017 guidance while achieving the highest annual production results to date," said Fernando E. Ganoza, CEO. "In the upcoming year, we will focus on increasing mineral resources through aggressive exploration at the El Roble mine and the surrounding prospective 6,600 hectare land package, to continue growing production and expanding the operation." Fourth Quarter and Full Year Operational Highlights Fourth Quarter Producti

Banque Fédérative du Credit Mutuel: Post Stabilisation Notice22.1.2018 18:54Pressemelding

PARIS, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Banque Fédérative du Credit Mutuel Post Stabilisation Notice HSBC (contact: Syndicate desk, telephone: +44 207 992 8066) hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities. Issuer: Banque Fédérative du Credit Mutuel Guarantor (if any): na Aggregate nominal amount: GBP 450,000,000 Description: 1.375% due Dec 2021 Offer price: 99.872 Stabilising Managers: HSBC & Goldman Sachs This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction This information is provided by RNS The company news service from the London Stock Exchange Contacts: RNS Customer Services 0044-207797-4400 rns@londonstockexchange.com http://www.rns.com This announ

Claroty Wins Inaugural S4 ICS Detection Challenge22.1.2018 18:42Pressemelding

Product Takes Top Spot in both Asset Discovery and Threat Detection Phases NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Claroty, an innovator in operational technology (OT) network protection, today announced that it was crowned winner of the inaugural S4 ICS Detection Challenge, which took place at the S4x18 Conference in Miami. Claroty's Continuous Threat Detection product claimed top honors in both the Phase I - Identification and Phase II - Detection segments of the challenge. During Phase I, contestants consumed network traffic captured from 15 different sites at an unidentified West Coast (U.S.) oil and gas company. The contestants were required to use their products to identify industrial control system (ICS) assets on the network and provide a view of how the assets were communicating. Contestants were rewarded for discovering assets, identifying specific details about them and were given bonus points for unique insights. Scoring was designed to test the products themselves, rat

CEO optimism booms despite increasing anxiety over threats to growth22.1.2018 18:30Pressemelding

· Optimism in global economic growth reaches record level and rises in all countries · US reinforces its lead on China as a target market for growth in 2018 · Over half of CEOs expect their headcount to increase · Terrorism, geopolitical uncertainty, cyber and climate change rise as threats to growth DAVOS, Switzerland, Jan. 22, 2018 (GLOBE NEWSWIRE) -- A record-breaking share of CEOs are optimistic about the economic environment worldwide, at least in the short term. That's one of the key findings of PwC's 21st survey of almost 1,300 CEOs around the world, launched today at the World Economic Forum Annual Meeting in Davos. Fifty seven percent of business leaders say they believe global economic growth will improve in the next 12 months. It's almost twice the level of last year (29%) and the largest ever increase since PwC began asking about global growth in 2012. Optimism in global growth has more than doubled in the US (59%) after a period of uncertainty surrounding the election (201

ShoCard Meets EU's GDPR 'Privacy by Design' Standards through its Identity Management Solutions22.1.2018 16:12Pressemelding

Blockchain-based identity management platform addresses provisions of EU data legislation CUPERTINO, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- ShoCard, a leading blockchain-based identity management system (IMS), today announces its technology meets the European Union's (EU) new regulatory framework for data, known as the General Data Protection Regulation (GDPR), "Privacy by Design" standards. The IMS removes the necessity for authentication data to be stored on organization databases. Instead, it is stored completely on the user's mobile device, secured with their private key and shared via the blockchain. Affected EU-based companies, as well as U.S.-based and other foreign-based companies, processing or holding the personal data of persons residing in the EU, no matter where they are located or where its data is processed within the region, are expected to have GDPR compliant solutions in place ahead of the legislation's enforcement date of May 25, 2018. With user privacy at the cor

Nasdaq Welcomes Cielo S.A. to the Nasdaq International Designation22.1.2018 15:30Pressemelding

NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) today announced that Cielo S.A. (BVMF:CIEL3) (OTC:CIOXY) (Nasdaq:CIOXY), a tech retail services company, leading the electronic payments sector in Latin America as one of the top 10 Brazilian corporations in terms of market value, is the latest company to join the Nasdaq International Designation. Through its membership, Cielo will have access to Nasdaq's investor relations services and unparalleled visibility assets to increase awareness with investors for their U.S.-traded Level 1 ADRs. The Nasdaq International Designation is available to non-U.S. companies that have Level 1 ADRs or shares that trade on the over-the-counter market. Cielo joins additional South American Member companies Minerva Foods S.A. (BVMF: BEEF3/OTC - Nasdaq Intl: MRVSY) and Marfrig Global Foods S.A. (BVMF: MRFG3/OTC - Nasdaq Intl: MRRTY). "We have seen strong sign of return to growth in South America and many companies are looking to tap int

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom